News about the advancement of 2 biosimilar candidates, ranibizumab and teriparatide, were recently reported.
Xbrane Biopharma of Sweden reported positive in-vitro biosimilarity data for Xlucane, the company’s ranibizumab biosimilar of Genentech (Roche)/Novartis’s reference product Lucentis, a treatment for wet age-related macular degeneration (AMD). The Xlucane study was conducted per biosimilar guidelines developed by both the FDA and European Medicines Agency (EMA), and used several pilot-scale R&D batches of Xlucane versus several batches of the reference product. Analyses evaluated 5 key structural components:
The company reported that it will address purity, which was said to be slightly low, during production scale-up.
Ranibizumab, a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab, inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A), which is responsible for excessive blood vessel development in the retina leading to progressive loss of vision. Ranibizumab is indicated for the treatment of AMD, macular edema, degenerative myopia, diabetes complications, and all ocular conditions that lead to vision loss.
With Lucentis facing patent expiration in June 2020 in the United States, and 2022 in Europe, all ranibizumab biosimilars are currently in development, except for Razumab, which was approved as a “similar biologic” in India in 2015.
San Diego-based Pfenex reported that the company’s teriparatide (PF708), a biosimilar of Eli Lilly’s osteoporosis treatment Forteo/Forsteo, began a phase 3 trial in December 2016 that is expected to be completed in April 2018. The study is designed to compare the effects of PF708 and Forteo in patients with osteoporosis and will compare anti-drug antibodies, plasma area-under-the-curve, and maximum concentration of teriparatide, in addition to mean percentage change in lumbar-spine bone mineral density.
Teriparatide is a recombinant form of parathyroid hormone (PTH) that is identical to a portion of human PTH, and is an effective bone-growing agent. Forteo/Forsteo is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women. The patents on Forteo/Forsteo will expire in the United States and in Europe in August 2019. The EMA’s Committee for Medicinal Products for Human Use recommended granting marketing authorization for the Movymia and Terrosa teriparatide biosimilars in November 2016. (India approved teriparatide “similar biologics” in 2010 and 2012; EMA notes that these drugs might not have been authorized following as a strict a regulatory process as is required by EMA.)
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.